Arbutus Biopharma Cp (ABUS) Stock Price, Quote & News

Company Profile

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reaw...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 469 0914

Website: www.arbutusbio.com

Address:

701 Veterans Circle, Warminster, United States

Pathtomyhome2 Sep. 16 at 6:53 AM

$ABUS honest question. This is my first time facing this “tender” situation. Can someone explain to me what this is and what’s the best choice? Appreciate it

0 · Reply

Afrozombie Sep. 15 at 9:54 PM

$ABUS Alight someone made 100k call that this stock would go to $10 which is either insane or someone knows something.

2 · Reply

Mountainmannn Sep. 15 at 9:16 PM

$ABUS I'm in for more! Don't understand, don't care to understand.... I just know we have been right the past few years and it feels great! I think it will continue with no doubt in my mind.

0 · Reply

DocPharm Sep. 15 at 8:29 PM

$ABUS first time I’ve seen the shares traded decrease after hours 4.25M —> 4.05M Crazy how they’re allowed such an allowance on their petty games Oh well, I’ll keep gobbling their discounts ;)

0 · Reply

DocPharm Sep. 15 at 7:40 PM

$ABUS tomorrow may be a good chance to scoop some gifts Anything below $5 is a no brainer while the Tender is running

2 · Reply

Grtgooglymoogly Sep. 15 at 7:31 PM

$ABUS In 2018, Tom Brady, while getting a massage, asked for a kiss from his 10 year old son. After getting a peck, he asked for another, longer kiss and received a long mouth to mouth kiss that creeped out people worldwide. The price of Abus peaked at $11.70 that year.....we'd all give Tom a long sloppy kiss for $11.70 again.

0 · Reply

DocPharm Sep. 15 at 6:29 PM

$ABUS Tom Brady first started Sept 30th; Tom Brady won the Super Bowl with MVP that same season. The first day following the close of the auction is 30 Sep; ABUS will become MVP Move over Bledsoe

2 · Reply

NoBSPls Sep. 15 at 4:23 PM

$ABUS Added 400 to test my theory

0 · Reply

CapitalismUSA Sep. 15 at 3:57 PM

$ABUS added 500 shares to my overflowing A-BUS.

0 · Reply

SpaceCityKid Sep. 15 at 3:38 PM

$ABUS Near the "floor" of the auction. Sure feels like a bargain here.

0 · Reply

Arbutus Biopharma commences $230M modified Dutch Auction tender offer

Aug 24, 2026, 7:30 AM EDT - 22 days ago

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

2026-08-21T11:40:40.000Z - 25 days ago

Arbutus Biopharma to repurchase $230M of shares through Dutch Auction

Aug 21, 2026, 7:30 AM EDT - 25 days ago

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

Aug 12, 2026, 7:30 AM EDT - 4 weeks ago

Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 12, 2026, 7:00 AM EDT - 4 weeks ago

Arbutus Biopharma Quarterly report: Q2 2026

Aug 12, 2026, 7:00 AM EDT - 4 weeks ago

Arbutus Biopharma Earnings release: Q2 2026

2026-07-16T11:50:33.000Z - 2 months ago

Arbutus Biopharma expects to return $230M in capital to shareholders

2026-07-16T11:45:21.000Z - 2 months ago

Arbutus initiates patent infringement actions against Pfizer, BioNTech

BNTX PFE ROIV

2026-07-16T11:45:13.000Z - 2 months ago

Arbutus Biopharma receives $178M settlement agreement from Moderna

MRNA

Jul 16, 2026, 7:30 AM EDT - 2 months ago

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

May 13, 2026, 7:30 AM EDT - 4 months ago

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026, 7:00 AM EDT - 4 months ago

Arbutus Biopharma Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 4 months ago

Arbutus Biopharma Earnings release: Q1 2026

2026-04-15T11:35:22.000Z - 5 months ago

Arbutus Biopharma granted Fast Track designation for imdusiran

Apr 15, 2026, 7:30 AM EDT - 5 months ago

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

Apr 14, 2026, 8:00 AM EDT - 5 months ago

Arbutus Biopharma Proxy statement: Proxy filing

Apr 14, 2026, 8:00 AM EDT - 5 months ago

Arbutus Biopharma Proxy statement: Proxy filing

2026-04-07T14:33:40.000Z - 5 months ago

Arbutus Biopharma price target lowered to $5.50 from $7 at Jefferies

MRNA

Mar 23, 2026, 7:30 AM EDT - 5 months ago

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Mar 23, 2026, 7:00 AM EDT - 5 months ago

Arbutus Biopharma Earnings release: Q4 2025

Mar 23, 2026, 7:00 AM EDT - 5 months ago

Arbutus Biopharma Annual report: Q4 2025

2026-03-04T16:55:47.000Z - 6 months ago

Why Is Moderna (MRNA) Stock Surging Today, 3/4/26?

MRNA

2026-03-04T11:49:13.000Z - 6 months ago

Moderna resolves litigation with Arbutus, to pay up to $2.25B in settlement

MRNA ROIV

Mar 3, 2026, 4:46 PM EST - 6 months ago

Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant

MRNA

Mar 3, 2026, 4:26 PM EST - 6 months ago

Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute

MRNA ROIV

2026-03-03T21:24:20.000Z - 6 months ago

Genevant, Arbutus announce $2.25B global settlement with Moderna

MRNA ROIV

Mar 3, 2026, 4:15 PM EST - 6 months ago

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

ROIV MRNA

Mar 3, 2026, 4:15 PM EST - 6 months ago

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

ROIV MRNA

Mar 3, 2026, 4:15 PM EST - 6 months ago

Moderna Resolves Global Patent Litigation with Arbutus/Genevant

MRNA

2026-02-02T19:50:34.000Z - 7 months ago

Arbutus faces higher bar to argue infringement by Moderna, says Jefferies

MRNA

2026-02-02T19:35:56.000Z - 7 months ago

Moderna reverses lower after court issues memo in patent fight with Arbutus

MRNA

Nov 13, 2025, 7:30 AM EST - 10 months ago

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 7:00 AM EST - 10 months ago

Arbutus Biopharma Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 10 months ago

Arbutus Biopharma Quarterly report: Q3 2025

Oct 7, 2025, 8:00 AM EDT - 11 months ago

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Arbutus Biopharma Earnings release: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Arbutus Biopharma Quarterly report: Q2 2025

Aug 6, 2025, 7:30 AM EDT - 1 year ago

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 25, 2025, 7:30 AM EDT - 1 year ago

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

May 14, 2025, 7:30 AM EDT - 1 year ago

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 7:30 AM EDT - 1 year ago

Arbutus Biopharma Quarterly report: Q1 2025

May 14, 2025, 7:30 AM EDT - 1 year ago

Arbutus Biopharma Earnings release: Q1 2025

May 7, 2025, 2:01 AM EDT - 1 year ago

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Apr 23, 2025, 2:01 AM EDT - 1 year ago

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Arbutus Biopharma Proxy statement: Proxy Filing

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Arbutus Biopharma Proxy statement: Proxy Filing

Mar 27, 2025, 7:56 AM EDT - 1 year ago

Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Mar 27, 2025, 7:30 AM EDT - 1 year ago

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Mar 27, 2025, 7:30 AM EDT - 1 year ago

Arbutus Biopharma Earnings release: Q4 2024

Mar 27, 2025, 7:30 AM EDT - 1 year ago

Arbutus Biopharma Annual report: Q4 2024

Mar 3, 2025, 9:15 AM EST - 1 year ago

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

ROIV

Feb 25, 2025, 7:00 AM EST - 1 year ago

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Jan 13, 2025, 7:30 AM EST - 1 year ago

Arbutus Provides 2025 Corporate and Financial Update

Dec 3, 2024, 11:00 AM EST - 1 year ago

Arbutus Biopharma Transcript: Status Update

Dec 3, 2024, 8:00 AM EST - 1 year ago

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Nov 26, 2024, 7:30 AM EST - 1 year ago

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Nov 21, 2024, 7:00 AM EST - 1 year ago

Arbutus Biopharma Transcript: Jefferies London Healthcare Conference 2024

Nov 15, 2024, 11:02 AM EST - 1 year ago

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Nov 14, 2024, 7:30 AM EST - 1 year ago

Arbutus to Present at Jefferies London Healthcare Conference

Nov 6, 2024, 8:45 AM EST - 1 year ago

Arbutus Biopharma Earnings Call Transcript: Q3 2024

Nov 6, 2024, 8:45 AM EST - 1 year ago

Arbutus Biopharma Quarterly report: Q3 2024

Nov 6, 2024, 8:45 AM EST - 1 year ago

Arbutus Biopharma Earnings release: Q3 2024

Nov 6, 2024, 7:00 AM EST - 1 year ago

Arbutus Biopharma Registration statement: Registration Filing

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Oct 15, 2024, 8:16 AM EDT - 1 year ago

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Oct 8, 2024, 1:30 PM EDT - 1 year ago

Arbutus Biopharma Transcript: H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Sep 10, 2024, 8:30 AM EDT - 2 years ago

Arbutus Biopharma Transcript: Baird's 2024 Global Healthcare Conference

Sep 9, 2024, 8:00 AM EDT - 2 years ago

Arbutus Biopharma Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 3, 2024, 7:30 AM EDT - 2 years ago

Arbutus to Participate in Two Upcoming Investor Conferences

Aug 1, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Earnings Call Transcript: Q2 2024

Aug 1, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Quarterly report: Q2 2024

Aug 1, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Earnings release: Q2 2024

Aug 1, 2024, 7:30 AM EDT - 2 years ago

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 18, 2024, 7:30 AM EDT - 2 years ago

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Jun 6, 2024, 11:15 AM EDT - 2 years ago

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Jun 5, 2024, 9:30 AM EDT - 2 years ago

Arbutus Biopharma Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 2:30 AM EDT - 2 years ago

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Jun 3, 2024, 9:50 AM EDT - 2 years ago

Arbutus Distributors Ltd. News Release

May 29, 2024, 7:30 AM EDT - 2 years ago

Arbutus to Participate in Jefferies Global Healthcare Conference

May 22, 2024, 2:00 AM EDT - 2 years ago

Arbutus to Present Imdusiran Data at EASL Congress 2024

May 20, 2024, 3:30 PM EDT - 2 years ago

Arbutus Biopharma Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 17, 2024, 9:00 AM EDT - 2 years ago

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

May 14, 2024, 9:30 AM EDT - 2 years ago

Arbutus Biopharma Transcript: The Citizens JMP Life Sciences Conference

May 2, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Earnings Call Transcript: Q1 2024

May 2, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Quarterly report: Q1 2024

May 2, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Earnings release: Q1 2024

May 2, 2024, 7:30 AM EDT - 2 years ago

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 2, 2024, 7:25 AM EDT - 2 years ago

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

Apr 18, 2024, 7:30 AM EDT - 2 years ago

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Arbutus Biopharma Proxy statement: Proxy Filing

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Arbutus Biopharma Proxy statement: Proxy Filing

Apr 4, 2024, 8:30 AM EDT - 2 years ago

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Mar 12, 2024, 2:05 PM EDT - 2 years ago

Arbutus Biopharma Transcript: Barclays 26th Annual Global Healthcare Conference 2024

Feb 29, 2024, 8:45 AM EST - 2 years ago

Arbutus Biopharma Earnings Call Transcript: Q4 2023

Feb 29, 2024, 8:45 AM EST - 2 years ago

Arbutus Biopharma Annual report: Q4 2023

Feb 29, 2024, 8:45 AM EST - 2 years ago

Arbutus Biopharma Earnings release: Q4 2023

Feb 29, 2024, 7:30 AM EST - 2 years ago

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Feb 15, 2024, 7:30 AM EST - 2 years ago

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Jan 8, 2024, 7:30 AM EST - 2 years ago

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Nov 15, 2023, 6:30 AM EST - 2 years ago

Arbutus Biopharma Transcript: 14th Annual Jefferies London Healthcare Conference 2023

Nov 9, 2023, 4:01 PM EST - 2 years ago

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Nov 9, 2023, 7:00 AM EST - 2 years ago

Arbutus Biopharma Slides: Corporate Presentation

Nov 7, 2023, 8:45 AM EST - 2 years ago

Arbutus Biopharma Earnings Call Transcript: Q3 2023

Nov 7, 2023, 8:45 AM EST - 2 years ago

Arbutus Biopharma Quarterly report: Q3 2023

Nov 7, 2023, 8:45 AM EST - 2 years ago

Arbutus Biopharma Earnings release: Q3 2023

Nov 7, 2023, 7:30 AM EST - 2 years ago

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 7:15 AM EST - 2 years ago

Arbutus Announces CEO, William Collier, to Retire December 31, 2023

Oct 24, 2023, 7:30 AM EDT - 2 years ago

Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Pathtomyhome2 Sep. 16 at 6:53 AM

$ABUS honest question. This is my first time facing this “tender” situation. Can someone explain to me what this is and what’s the best choice? Appreciate it

0 · Reply

Afrozombie Sep. 15 at 9:54 PM

$ABUS Alight someone made 100k call that this stock would go to $10 which is either insane or someone knows something.

2 · Reply

Mountainmannn Sep. 15 at 9:16 PM

$ABUS I'm in for more! Don't understand, don't care to understand.... I just know we have been right the past few years and it feels great! I think it will continue with no doubt in my mind.

0 · Reply

DocPharm Sep. 15 at 8:29 PM

0 · Reply

DocPharm Sep. 15 at 7:40 PM

$ABUS tomorrow may be a good chance to scoop some gifts Anything below $5 is a no brainer while the Tender is running

2 · Reply

Grtgooglymoogly Sep. 15 at 7:31 PM

0 · Reply

DocPharm Sep. 15 at 6:29 PM

$ABUS Tom Brady first started Sept 30th; Tom Brady won the Super Bowl with MVP that same season. The first day following the close of the auction is 30 Sep; ABUS will become MVP Move over Bledsoe

2 · Reply

NoBSPls Sep. 15 at 4:23 PM

$ABUS Added 400 to test my theory

0 · Reply

CapitalismUSA Sep. 15 at 3:57 PM

$ABUS added 500 shares to my overflowing A-BUS.

0 · Reply

SpaceCityKid Sep. 15 at 3:38 PM

$ABUS Near the "floor" of the auction. Sure feels like a bargain here.

0 · Reply

DocPharm Sep. 15 at 2:58 PM

$ABUS adding a few

0 · Reply

NoBSPls Sep. 15 at 1:30 PM

$ABUS Here’s one theory. Nobody who bought in the last year paid more than $5.45. So, I don’t see the final tender offer being much higher than that. Enough weak/tired hands and flippers to fill the share target. For my part, I am convinced any BO or merger will be at a SP considerably above that. I hope to profit on the impatience of others

0 · Reply

Blueviking Sep. 15 at 8:22 AM

$ABUS I dont have a tender ass!!

0 · Reply

Mountainmannn Sep. 14 at 11:54 PM

$ABUS

0 · Reply

Heavey Sep. 14 at 8:03 PM

$ABUS

0 · Reply

SpaceCityKid Sep. 14 at 1:03 PM

$ABUS As of 08/31/2026, Short Interest @ 18,916,119 shares

0 · Reply

AhMrBond Sep. 12 at 4:45 PM

$ABUS tender my shares for 5 bucks??? It's over that as it is if i wanted to sell all now. What utter clown came up with this???

0 · Reply

LM_Johanssen Sep. 11 at 3:17 PM

$ABUS I’m heavily considering tendering all my shares (>100k) and buying back next month.

6 · Reply

Heavey Sep. 11 at 2:04 PM

$ABUS can’t see us getting out of the $5.05 - $5.20 range until after Sept 29. These 5 weeks will drag on. Prove me wrong MMs.

1 · Reply

Heavey Sep. 11 at 12:34 PM

$ABUS would be nice if we had a green day today

0 · Reply

ThinkinLongTerm Sep. 10 at 11:48 PM

$ABUS Whats‘s the reason behind this buyback? Everything I’ve read said it was just “a return of capital to shareholders,” but I don’t see where it was a belief in the stock being undervalued. Can anyone help point to a release? I’m in this for long haul through Moderna outcome, Pfizer outcome, then HBV. Moderna. half check. Pfizer… up next. HBV… who knows?

2 · Reply

DocPharm Sep. 10 at 8:38 PM

$ABUS my guy! I hope it goes to 4.88 I’ll literally clear out my savings and then tender all of the shares immediately to recoup the cost and keep the freebies

1 · Reply

Market Cap	592.57M
Revenue (ttm)	18.14M
Net Income (ttm)	-72.85M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	649,900
Avg Vol	936,122
Day's Range	N/A - N/A
Shares Out	188.72M
Stochastic %K	2%
Beta	1.98
Analysts	Strong Sell
Price Target	$4.50